Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study

Original from: Tempus

Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset for patients with NSCLC to facilitate future novel research related to precision medicine, diagnostic development, and biomarker discovery.

The study is open for enrollment for two cohorts of patients, one of which will focus on patients who have been recently diagnosed with Stage IV NSCLC and will receive standard of care checkpoint inhibitor therapy, and the other cohort will focus on patients who have early-stage NSCLC and are candidates for surgery. Tempus is leveraging its comprehensive molecular profiling portfolio – including its solid tumor assay, xT, liquid biopsy, xF, and an investigational minimal residual disease (MRD) assay – throughout the study to better understand this high-need patient population on a longitudinal basis. Patients enrolled in the trial will be studied for up to three years to assess the impact of their underlying tumor biology on disease progression and therapy efficacy. The results of this study will be used for biomarker discovery, including potential use of circulating tumor DNA (ctDNA) testing to measure MRD.

“The GEMINI study addresses research gaps in a high-need patient population that the Tempus platform is uniquely positioned to undertake,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “By taking a multi-omics approach, we believe that we can generate one of the most comprehensive analyses of early and late stage NSCLC patients, and one that will power significant advancements in biomarker discovery.”

The study employs the full power of Tempus’ platform, including its intelligent diagnostics, multimodal data library, and clinical trial matching program (TIME), to develop a powerful multi-omic dataset at scale. In leveraging its TIME Trial Network, Tempus is broadening access to patients in communities across the country, while also helping to ensure that the study’s results are representative of this patient population in the United States. 

​Source: Tempus Announces the GEMINI Non-Small Cell Lung Cancer Study